На этой странице перечислены больницы направления «Кардиология» (включая Double Valve Replacement) в Хайдарабад, Индия, включая KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills.
Спросите нас о «Double Valve Replacement» в Хайдарабад, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 4 аккредитованных больниц (Кардиология) в Хайдарабад, Индия
Рекомендуем🇮🇳 KIMS Hospitals, Secunderabad
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 743 отзывов).
🇮🇳 Yashoda Hospitals, Secunderabad
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 518 отзывов).
🇮🇳 Apollo Hospital DRDO
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 82 отзывов).
🇮🇳 Apollo Hospitals, Jubilee Hills
Больница занимает 4-е место в этом списке по указанному рейтингу (4.1/5, 44 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Кардиология» указано среди её специализаций и она находится в Хайдарабад, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «double valve replacement» в Хайдарабад, Индия?
Выбор подходящей больницы для «double valve replacement» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Кардиология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Double Valve Replacement»
Double Valve Replacement (DVR) is an open-heart surgical procedure in which two diseased cardiac valves — most commonly the mitral and aortic — are simultaneously excised and replaced with either mechanical prostheses or bioprosthetic tissue valves, restoring normal hemodynamic flow and relieving the chronic pressure overload that causes irreversible ventricular remodeling. Performed by high-volume cardiac surgical teams, the procedure carries an in-hospital success rate of approximately 92–95% at accredited centers, with five-year survival exceeding 80% in appropriately selected patients. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-accredited centers in the UAE, offering end-to-end coordination that reduces cost, wait time, and logistical complexity for families traveling from across Africa, the Middle East, Central Asia, and beyond. Hospital Stay: 10–14 days (including 3–5 days in the Cardiac ICU followed by a step-down ward) • Total Stay in Country (Fit-to-Fly): 6–8 weeks post-surgery before clearance for long-haul international flight (surgeon sign-off and repeat echocardiogram required) • Success Rate: 92–95% in-hospital procedural success at accredited high-volume cardiac centers
Clinical Overview
Double Valve Replacement addresses concurrent pathology of two cardiac valves, most frequently the aortic and mitral valves, though tricuspid–mitral and aortic–tricuspid combinations are also encountered. The underlying etiologies include rheumatic heart disease (the predominant cause in South Asia and sub-Saharan Africa), degenerative calcific disease, infective endocarditis with multi-valve involvement, connective tissue disorders such as Marfan syndrome, and congenital malformations including bicuspid aortic valve with coexisting mitral prolapse. When two valves are simultaneously dysfunctional — through stenosis, regurgitation, or mixed lesions — the left ventricle is subjected to a combined volume and pressure burden that accelerates chamber dilation, systolic dysfunction, pulmonary hypertension, and ultimately irreversible myocardial fibrosis. Timely surgical intervention is therefore critical before the ejection fraction declines below 30–35% or irreversible pulmonary vascular changes develop. The physiological impact of dual valvular disease is compounding rather than additive. Aortic stenosis imposes a fixed outflow obstruction that forces the ventricle to generate supranormal systolic pressures, causing concentric hypertrophy; simultaneous mitral regurgitation then decompresses the overloaded ventricle into the left atrium, masking the true severity of aortic disease on standard gradient measurements. This complex interplay requires careful pre-operative hemodynamic assessment — including right and left heart catheterization, three-dimensional transesophageal echocardiography (3D-TEE), and gated cardiac CT angiography — to accurately characterize each valve lesion, quantify ventricular function, assess annular dimensions for prosthesis sizing, and evaluate concomitant coronary artery disease that may necessitate bypass grafting at the same operative sitting. The global standard of care for Double Valve Replacement is cardiopulmonary bypass (CPB)-supported open-heart surgery performed through a full median sternotomy or, in selected patients, a minimally invasive right anterolateral mini-thoracotomy or upper hemi-sternotomy. Myocardial protection is achieved with cold crystalloid or del Nido cardioplegia, delivered antegrade via the aortic root and retrograde via the coronary sinus. Prosthesis selection — mechanical (bileaflet St. Jude Medical / On-X valves) versus bioprosthetic (Carpentier-Edwards PERIMOUNT Magna, Medtronic Mosaic, or Hancock II) — is individualized based on patient age, lifestyle, anticoagulation compliance, comorbidities, and reproductive planning. Post-operatively, patients are managed in a dedicated cardiac ICU with invasive hemodynamic monitoring, transesophageal echocardiographic surveillance for prosthetic valve function, lung-protective ventilation, and early extubation protocols targeting liberation from mechanical ventilation within 6–12 hours.
Who is a Candidate?
• ELIGIBLE PATIENTS: • Adults with confirmed dual valvular pathology (most commonly aortic + mitral) documented by echocardiography and/or cardiac catheterization • Symptomatic patients in NYHA functional Class II–IV despite optimized medical therapy (diuretics, ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists) • Asymptomatic patients with objectively impaired left ventricular systolic function (LVEF ≤ 50–55%) attributable to valvular volume overload • Patients with severe aortic stenosis (aortic valve area < 1.0 cm², mean gradient > 40 mmHg) and coexisting moderate-to-severe mitral regurgitation or stenosis • Rheumatic multi-valve disease with progressive symptoms and favorable annular anatomy for prosthetic implantation • Patients with active or healed infective endocarditis involving two valves after an appropriate course of pathogen-directed IV antibiotics and confirmed sterile blood cultures • Patients undergoing redo sternotomy for prior single-valve repair failure who now require contralateral valve replacement • Patients in whom concomitant CABG for significant coronary artery disease (≥ 70% stenosis in major epicardial vessels) is planned at the same operative sitting • REQUIRED PRE-OPERATIVE DIAGNOSTICS: • 2D and 3D Transthoracic Echocardiogram (TTE) with Doppler: valvular morphology, gradients, valve areas, regurgitant volumes, LVEF, pulmonary artery pressures • Transesophageal Echocardiogram (TEE): annular sizing, subvalvular apparatus integrity, thrombus exclusion, intraoperative guidance • Gated Cardiac CT Angiography (256-slice or higher): aortic root geometry, annular dimensions for prosthesis sizing, coronary anatomy, calcium scoring • Right and Left Heart Catheterization: hemodynamic quantification (PCWP, CO, PVR, SVR, Gorlin formula valve areas), coronary angiography • Pulmonary Function Tests (PFTs): baseline pulmonary reserve for CPB risk stratification • Carotid Doppler Ultrasound: preoperative stroke risk assessment • Complete blood count, coagulation profile (INR, aPTT), renal and hepatic function panels, HbA1c, thyroid function • Blood group and crossmatch (minimum 4–6 units PRBC reserved) • Chest X-ray (PA and lateral) and 12-lead ECG • RELATIVE AND ABSOLUTE CONTRAINDICATIONS: • Severely reduced LVEF (< 20%) with end-stage cardiomyopathy and no expected hemodynamic benefit from valve surgery • Severe irreversible pulmonary arterial hypertension (PVR > 8 Wood units unresponsive to vasodilator challenge) • Active systemic infection or bacteremia (surgery deferred until source control and sterile blood cultures for ≥ 72 hours) • Uncontrolled coagulopathy or hematologic malignancy precluding safe anticoagulation with mechanical prostheses • High operative mortality (EuroSCORE II > 20% or STS-PROM > 15%) in frail elderly patients — multidisciplinary heart team evaluation mandatory; TAVI + MitraClip as hybrid alternatives may be explored • Severe hepatic cirrhosis (Child-Pugh Class C) with coagulopathy refractory to correction • Prior mediastinal radiation with hostile mediastinum — requires individualized surgical planning
Treatment Options & Approaches
STANDARD APPROACH — CONVENTIONAL DOUBLE VALVE REPLACEMENT VIA MEDIAN STERNOTOMY: This remains the reference standard and is performed through a full median sternotomy with establishment of cardiopulmonary bypass (CPB) via aortic and bicaval venous cannulation. The aorta is cross-clamped and myocardial arrest is induced with cold antegrade/retrograde del Nido or Buckberg cardioplegia. The aortic valve is approached first (transverse aortotomy), followed by the mitral valve (via left atriotomy through the interatrial groove or the transseptal/superior approach depending on atrial anatomy). Both diseased native valves are excised with meticulous decalcification of the annuli, annular sizing, and interrupted or continuous suture implantation of the prostheses. Rewarming, de-airing, and weaning from CPB are performed under TEE guidance. Simultaneous tricuspid annuloplasty (DeVega or ring annuloplasty with Cosgrove-Edwards or Edwards MC3 rings) is added in approximately 30–40% of cases with coexisting functional tricuspid regurgitation. PROSTHESIS SELECTION — MECHANICAL vs. BIOPROSTHETIC: • Mechanical Valves (e.g., St. Jude Medical Regent, On-X, CarboMedics): Bileaflet pyrolytic carbon design; excellent long-term durability (> 20–30 years); require lifelong anticoagulation with warfarin (target INR 2.0–3.5 depending on valve position and thromboembolic risk); preferred in patients < 60–65 years with reliable anticoagulation access and no contraindication to warfarin. • Bioprosthetic Valves (e.g., Carpentier-Edwards PERIMOUNT Magna Ease, Medtronic Mosaic Ultra, Hancock II, bovine pericardial Edwards INTUITY): No lifelong anticoagulation required after the first 3–6 months (aspirin ± warfarin bridging); valve durability 15–20 years; preferred in patients ≥ 65–70 years, women of childbearing age, patients in geographies with unreliable INR monitoring, or those with anticoagulation contraindications. Structural valve deterioration (SVD) may necessitate redo surgery or transcatheter valve-in-valve (ViV-TAVI / ViV-TMVI) intervention. • Homograft / Allograft Valves: Human cadaveric aortic or pulmonary valves; reserved for active aortic root endocarditis or complex reconstruction; limited availability. MINIMALLY INVASIVE DOUBLE VALVE REPLACEMENT (MI-DVR): In carefully selected patients without prior cardiac surgery, significant obesity, or pericardial adhesions, both valves can be replaced through a right anterolateral mini-thoracotomy (5–8 cm incision) or upper hemi-sternotomy (J- or T-sternotomy). Peripheral CPB (femoral artery and vein cannulation) and endoscopic/video-assisted techniques are employed. Benefits include reduced blood loss (40–60% less transfusion requirement), shorter ICU stay (1–2 days), reduced wound complications, faster return to full activity (4–5 weeks vs. 8–12 weeks for full sternotomy), and superior cosmesis. This approach requires a center performing > 100 minimally invasive valve procedures per year and is available at select GAF Healthcare partner institutions in India and the UAE. ROBOTIC-ASSISTED VALVE SURGERY: Da Vinci robotic systems allow mitral valve surgery with wristed instrument articulation through 8–12 mm ports, though true simultaneous robotic double valve replacement remains technically demanding and is performed at only a handful of centers globally. More commonly, robotic assistance is used for the mitral component while the aortic valve is addressed through a small aortotomy. Available at select partner centers in Chennai, Mumbai, and Dubai. HYBRID / TRANSCATHETER ALTERNATIVES FOR HIGH-RISK PATIENTS: For patients deemed inoperable or at extreme surgical risk (EuroSCORE II > 15%), a hybrid approach may be considered: Transcatheter Aortic Valve Implantation (TAVI/TAVR) — using balloon-expandable (Edwards SAPIEN 3 Ultra) or self-expanding (Medtronic Evolut PRO+, Boston Scientific Acurate neo2) systems — combined with transcatheter mitral edge-to-edge repair (MitraClip NTR/XTR or PASCAL Precision system) in a staged or simultaneous procedure. This avoids the risks of sternotomy and CPB in frail patients with multiple comorbidities. CONGOMITANT PROCEDURES FREQUENTLY PERFORMED AT THE SAME OPERATIVE SITTING: • Coronary Artery Bypass Grafting (CABG) for significant CAD • Surgical ablation for atrial fibrillation (Cox-Maze IV procedure using radiofrequency or cryoablation energy) • Left Atrial Appendage Ligation or stapling (stroke prevention) • Tricuspid valve repair (ring annuloplasty) • Ascending aortic replacement for concomitant aneurysm
Восстановление
PHASE 1 — PRE-ARRIVAL & REMOTE EVALUATION (2–4 weeks before travel): • Patient submits medical records, echocardiograms, catheterization reports, and recent labs to GAF Healthcare's clinical coordination team • GAF's partner cardiac surgeon conducts a video teleconsultation, reviews all imaging, calculates EuroSCORE II / STS-PROM operative risk scores, and confirms surgical candidacy • Prosthesis type (mechanical vs. bioprosthetic), surgical approach (conventional vs. minimally invasive), and concomitant procedures are planned • GAF Healthcare initiates e-Medical Visa application for India or UAE entry arrangements • Anticoagulation bridging protocol issued (e.g., stopping warfarin 5 days pre-op, bridging with LMWH) PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in-country): • Airport pick-up by GAF's dedicated medical escort team; transfer to pre-arranged accommodation or hospital-affiliated guesthouse for attendant • Formal in-person consultation with operating cardiac surgeon and cardiac anesthesiologist • Complete pre-operative investigations: 3D-TEE, cardiac CT angiography (if not performed remotely), coronary angiography, PFTs, full blood panel, crossmatch, INR, carotid Doppler • Multidisciplinary Heart Team (cardiac surgeon, interventional cardiologist, cardiac anesthesiologist, perfusionist, intensivist) case conference • Pre-anesthetic assessment; optimization of blood glucose, hemoglobin (target Hb ≥ 10 g/dL pre-op), electrolytes, and renal function • Informed consent obtained with GAF-provided language interpreter • Patient admitted to hospital the evening before surgery; NPO after midnight PHASE 3 — THE OPERATION (Day 4 — approximately 5–8 hours): • Induction of general endotracheal anesthesia with invasive arterial line, central venous catheter, pulmonary artery catheter (Swan-Ganz), and intraoperative TEE probe • Median sternotomy or minimally invasive incision; systemic heparinization; CPB established • Myocardial arrest with cold cardioplegia; aortic cross-clamp time typically 90–150 minutes for double valve replacement • Sequential excision and replacement of aortic valve (transverse aortotomy) and mitral valve (left atriotomy) • Any concomitant procedures performed (CABG, Maze, tricuspid repair, LAA ligation) • Systematic de-airing of cardiac chambers under TEE guidance; aortic clamp released; cardiac rhythm restored (spontaneous or DC cardioversion) • CPB weaning with inotropic support (dopamine, milrinone, norepinephrine as needed); TEE confirmation of prosthetic valve function (no paravalvular leak, normal leaflet motion, gradients within acceptable range) • Protamine reversal of heparin; meticulous hemostasis; chest drain placement; sternal closure with wire cerclage PHASE 4 — CARDIAC ICU (Days 4–8): • Mechanically ventilated for 6–12 hours post-op with lung-protective strategy (target PaO2/FiO2 > 200) • Continuous hemodynamic monitoring: arterial BP, CVP, PA pressures, cardiac output via thermodilution • Chest drain output monitored hourly (re-exploration threshold: > 200 mL/hour × 3 hours) • Early extubation protocol; transition from IV to oral analgesia; incentive spirometry initiated • Warfarin initiated on post-operative Day 1–2 for mechanical valve recipients; target INR 2.5–3.5 (mitral mechanical) or 2.0–3.0 (aortic mechanical) • Bioprosthetic valve recipients receive aspirin 75–100 mg daily ± warfarin for the first 3 months • Rhythm monitoring for post-operative atrial fibrillation (incidence 30–40%); rate control (beta-blockers, amiodarone) and anticoagulation management • Repeat bedside TTE on post-op Day 2–3 to confirm prosthetic function and rule out pericardial effusion PHASE 5 — STEP-DOWN WARD (Days 8–14): • Transfer from ICU when hemodynamically stable, extubated, and on oral medications • Cardiac rehabilitation Phase I: supervised ambulation progressing from bedside sitting → corridor walking → stair climbing • Daily INR monitoring and warfarin dose adjustment • Chest drain removal (typically Day 1–3 post-op); wound care and sternal precaution education • Dietary counseling (low-sodium, vitamin K-consistent diet for warfarin users) • Patient and attendant education on mechanical valve anticoagulation management, INR self-testing, signs of prosthetic valve thrombosis (sudden dyspnea, decreased valve click), and endocarditis prophylaxis • Discharge planning: prescription for 3-month medication supply, INR monitoring schedule, dietary guidance documents in patient's native language PHASE 6 — POST-DISCHARGE IN-COUNTRY RECOVERY (Weeks 2–8): • Patient stays in GAF-arranged recovery accommodation near the hospital for a minimum of 4–6 weeks post-surgery • Outpatient follow-up at Week 2: wound inspection, sternal healing assessment, repeat TTE, INR check, 6-minute walk test • Outpatient follow-up at Week 4–6: repeat TTE confirming stable prosthetic valve gradients, LVEF trend, resolution of pulmonary hypertension; chest X-ray; sternal stability confirmed clinically • Milestone for flight clearance (Week 6–8): LVEF ≥ 40%, stable INR in therapeutic range, sternal stability, no active infection, no pericardial or pleural effusion on imaging, no arrhythmia requiring IV management • Surgeon issues Fit-to-Fly certificate; GAF Healthcare provides complete discharge summary, imaging CDs, and medication plan for the patient's home cardiologist PHASE 7 — LONG-TERM RECOVERY AT HOME (Months 2–12): • Full sternal healing: 8–12 weeks; no lifting > 5 kg or strenuous upper body activity during this period • Return to sedentary desk work: 6–8 weeks post-op • Return to moderate physical activity and driving: 8–12 weeks (surgeon-dependent) • Annual echocardiographic surveillance for life: prosthetic valve function, ventricular remodeling, detection of structural valve deterioration • Lifelong endocarditis prophylaxis with amoxicillin (or clindamycin if penicillin-allergic) before invasive dental or urological procedures • INR monitoring: weekly for first month, then monthly when stable (mechanical valve recipients)
Возможные риски
Double Valve Replacement carries a well-characterized risk profile that is thoroughly discussed with every patient during pre-operative counseling. In-hospital mortality at high-volume JCI-accredited centers ranges from 3–8%, stratified heavily by pre-operative LVEF, degree of pulmonary hypertension, renal function, and presence of concomitant CABG (EuroSCORE II and STS-PROM calculators are used to provide individualized estimates). Perioperative stroke occurs in 1.5–3% of cases, attributable to air embolism, atheroembolism from aortic manipulation, or post-operative atrial fibrillation; neuromonitoring with cerebral oximetry (NIRS) and rigorous de-airing protocols mitigate but do not eliminate this risk. Post-operative atrial fibrillation is the most common early complication (30–40%), typically managed with amiodarone and anticoagulation without long-term sequelae. Renal dysfunction or acute kidney injury occurs in 5–15% of patients (higher in those with pre-existing CKD or prolonged CPB time); temporary renal replacement therapy is required in approximately 2–5%. Prosthetic valve thrombosis is a life-threatening emergency occurring in approximately 0.3–1.3% per patient-year with mechanical valves, underscoring the critical importance of lifelong INR monitoring and patient education. Structural valve deterioration (SVD) in bioprosthetic valves requires redo surgery or transcatheter valve-in-valve (ViV) intervention in 15–30% of patients at 15–20 years — a key consideration when counseling younger patients on prosthesis choice. Paravalvular leak, bleeding requiring re-exploration (3–5%), deep sternal wound infection (1–2%), and prolonged ventilation (> 48 hours) are additional recognized risks. Patients traveling internationally must be counseled that any of these complications could significantly extend their in-country stay beyond the planned 6–8 weeks; GAF Healthcare ensures that all partner hospitals maintain cardiac surgery intensive care and re-intervention capabilities, and that patients carry a comprehensive surgical summary and emergency contact protocol for their home country cardiologist.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end medical tourism coordination for Double Valve Replacement patients traveling to India or the UAE, covering every logistical dimension from the first inquiry to safe repatriation. VISA & DOCUMENTATION — INDIA: • GAF facilitates the Indian e-Medical Visa (e-MV), which is available to nationals of 156 countries and allows a 60-day stay extendable up to 6 months — sufficient to cover the full 6–8-week post-operative recovery period • The e-MV includes a companion Medical Attendant Visa (e-MATv) for one accompanying family member • GAF's documentation team prepares the invitation letter from the treating hospital (mandatory for e-MV), assists with online application submission, and tracks approval status • Express processing available for urgent cases VISA & DOCUMENTATION — UAE (DUBAI / ABU DHABI): • Nationals of over 50 countries (including GCC citizens, EU passport holders, US, UK, and many African and Asian nations) receive visa-free entry or visa-on-arrival to the UAE • For nationalities requiring advance visa, GAF coordinates a UAE Medical / Treatment Visa application with partner hospital sponsorship through the General Directorate of Residency and Foreigners Affairs (GDRFA) • Extended stay permits are arranged for patients requiring > 30-day recovery • Health insurance liaison with DHA-empanelled insurance providers for eligible patients AIRPORT & GROUND TRANSFERS: • Dedicated medical escort or wheelchair-accessible vehicle arranged for arrival pickup at all major airports (Delhi IGI, Mumbai CSIA, Chennai MAA, Hyderabad HYD; Dubai DXB/DWC, Abu Dhabi AUH) • All vehicles are air-conditioned, GPS-tracked, and driven by GAF-vetted chauffeurs familiar with hospital routes • Hospital admission pre-arranged so patients proceed directly to the ward without waiting in general queues ACCOMMODATION FOR PATIENT & ATTENDANT: • GAF partners with hospital-affiliated guesthouses and nearby serviced apartments within 500m–2km of the treating hospital, priced from budget to premium depending on preference • Accommodation is equipped with kitchenette, housekeeping, and 24-hour security — suitable for attendants staying 6–8 weeks • Meal services tailored to post-cardiac surgery dietary requirements (low-sodium, low-fat, cardiac-friendly menus) arranged on request LANGUAGE & CULTURAL SUPPORT: • Dedicated bilingual case coordinators fluent in Arabic, French, Swahili, Russian, Bengali, and other languages assigned to each case • Certified medical interpreters present for all key consultations, consent discussions, and post-operative family briefings • Religious and dietary requirements (Halal meals, prayer arrangements) accommodated at all partner hospitals CLINICAL COORDINATION: • GAF's in-country clinical liaison officer conducts daily check-ins during the hospital stay and weekly visits during recovery accommodation stay • Telemedicine follow-up sessions with the operating surgeon organized for Months 3, 6, and 12 post-discharge • Complete medical records (operative notes, echocardiogram reports, discharge summary, INR log, imaging CDs) compiled and transmitted to the patient's home cardiologist via secure encrypted portal • Emergency 24/7 helpline for patients and attendants throughout the in-country stay
Частые вопросы о процедуре «Double Valve Replacement»
What is the cost of Double Valve Replacement in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after Double Valve Replacement?
What is the success rate of Double Valve Replacement?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «double valve replacement» в Хайдарабад, Индия
Найдите лучшие больницы для «double valve replacement» в Хайдарабад, Индия
На этой странице представлено 4 больниц в Хайдарабад, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Double Valve Replacement» в Хайдарабад, Индия
Сколько больниц направления «Кардиология» представлено в Хайдарабад, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Хайдарабад, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Double Valve Replacement» в Хайдарабад, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.